|
Summary of reviewed articles |
|||
| Authors |
Chemotherapeutic agent |
QOL measure |
Direction of effect |
|
|
|||
| Tannock et al. (1996) |
Mitoxantrone |
EORTC QLQ-30; Pain rating |
Improved pain, mood & physical activity |
| Beer et al., (2001) |
Docetaxel |
Present Pain Intensity scale |
Improved pain |
| Sinibaldi et al. (1999) |
Docetaxel |
Brief Pain Inventory |
Improved pain |
| Copur et al. (2001) |
Docetaxel |
Numeric rating scale |
Improved pain |
| Gravis et al. (2003) |
Docetaxel |
EORTC QLQ-30; Pain VAS |
Improved role, social functioning, overall QOL, pain, fatigue, constipation |
| Small et al. (2000) |
Suramin |
Brief Pain Inventory |
Improved pain |
| Fuse et al. (1996) |
Cisplatin/carboplatin |
Rating scale |
Improved pain |
| Kreis et al. (1999). |
Docetaxel |
Physician-graded events |
Presence of fatigue dose-limiting factor |
| Hamilton et al. (2003) |
Vinblastine |
Physician-graded events |
Presence of fatigue dose-limiting factor |
| van Andel et al. (2003) |
Epirubicin |
QLQ-30 |
Reduced fatigue, transient improvement in emotional, social and cognitive functioning |
| Kornblith et al. (2001) |
Docetaxel |
FACT-P, Mental Health Inventory-17 |
Transient improvements in emotional well-being, improved overall QOL |
Trask Health and Quality of Life Outcomes 2004 2:37 doi:10.1186/1477-7525-2-37 |
|||